

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

Article I. Objectives and Scope of Application

1. Objective of Establishment: These Principles are established to assist the Company in fostering a corporate culture of ethical management (or integrity management) and to ensure sound development, providing a framework for establishing robust business operations.
2. Scope of Application: These Principles apply to the Company's group enterprises and organizations (hereinafter referred to as "Group Enterprises and Organizations"), including the Company's subsidiaries, foundations whose cumulative funding from the Company directly or indirectly exceeds fifty percent (50%), and other institutions or legal entities over which the Company possesses substantive control.

Article II. Prohibition of Dishonest Conduct

1. The Company's Directors, Managerial Officers, Employees, Appointees, or persons who possess Substantive Control (hereinafter referred to as "Substantive Controllers") shall, in the course of engaging in business activities, neither directly nor indirectly offer, promise, request, or accept any improper benefits, nor engage in any other dishonest conduct, such as acts violating integrity, unlawful activities, or breaches of fiduciary duty, for the purpose of obtaining or maintaining benefits (hereinafter referred to as "Dishonest Conduct").
2. The parties subject to the preceding paragraph include:
Public Officials, political candidates, political parties, or party functionaries.
Any public or private enterprises or institutions, and their directors, supervisors, managerial officers, employees, substantive controllers, or other stakeholders.

Article III. Definition of Benefits

The term "benefits" as referred to in these Principles denotes anything of value, including, but not limited to, money, gifts, commissions, positions, services, preferential treatment, or rebates in any form or under any name.

This definition shall not apply to instances where the benefit is consistent with normal social courtesies, is provided occasionally, and presents no potential risk of affecting specific rights and obligations.

Article IV. Compliance with Laws and Regulations

The Company shall comply with the Company Act, the Securities and Exchange Act, the Business Entity Accounting Act, the Political Donations Act, the Anti-Corruption Act (or Statute for the Prevention of Corruption), the Government Procurement Act, the Act on Recusal of Public Servants from Conflicts of Interest, relevant Listing and OTC Regulations, and any other statutes pertaining to business conduct. This adherence serves as the fundamental prerequisite for the

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

implementation of ethical management.

Article V. Policy Statement

The Company shall, based on the operating philosophy of integrity, transparency, and accountability, formulate a policy founded upon ethical principles. This policy must be adopted by the Board of Directors. Concurrently, the Company shall establish robust corporate governance and risk control mechanisms to foster an operating environment conducive to sustainable development.

Article VI. Prevention Programs

1. The Company's established ethical management policy shall clearly and comprehensively stipulate specific practices for integrity management and prevention programs against dishonest conduct (hereinafter referred to as the "Prevention Programs"). These programs shall encompass operational procedures, conduct guidelines, and training.
2. The Prevention Programs established by the Company shall comply with the relevant laws and regulations of the locations where the Company and its Group Enterprises and Organizations operate.
3. The Company shall engage in communication with its employees, labor unions, major business partners (or trading counterparts), and other stakeholders during the process of formulating the Prevention Programs.

Article VII. Scope of the Prevention Programs

The Company shall establish a risk assessment mechanism for dishonest conduct to periodically analyze and evaluate business activities within its operational scope that bear a higher risk of dishonest conduct. Based on this assessment, the Company shall formulate Prevention Programs and regularly review their appropriateness and effectiveness.

The Company is advised to formulate Prevention Programs by referencing domestic and international general standards or guidelines. The Programs shall, at a minimum, encompass preventive measures for the following types of conduct:

- (1) Bribery and the Acceptance of Bribes (or Acceptance of Unlawful Benefits).
- (2) Providing Unlawful Political Donations.
- (3) Inappropriate charitable donations or sponsorships.
- (4) Providing or accepting unreasonable gifts, hospitality, or other improper benefits.
- (5) Infringement of trade secrets, trademarks, patents, copyrights, and other intellectual property rights (IPR).
- (6) Engaging in acts of unfair competition.

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

(7) Acts that directly or indirectly harm the rights, health, and safety of consumers or other stakeholders during the research and development, procurement, manufacturing, provision, or sale of products and services.

Article VIII. Commitment and Implementation

1. The Company shall require its Directors and Senior Management to issue a statement affirming their compliance with the ethical management policy, and shall mandate employee adherence to the ethical management policy as a condition of employment.
2. The Company and its Group Enterprises and Organizations shall clearly state their ethical management policy in their internal rules and regulations, external documents, and corporate website. They shall also explicitly state the commitment of the Board of Directors and Senior Management to proactively implement the ethical management policy and ensure its practical execution throughout internal management and business activities.
3. The Company shall produce and properly retain documented information regarding the ethical management policy, statements, commitments, and implementation described in Paragraphs 1 and 2.

Article IX. Ethical Business Activities

1. The Company shall conduct its business activities in a fair and transparent manner, fundamentally adhering to the principles of ethical management.
2. Prior to engaging in any business relationship, the Company shall assess the legality and the involvement of any dishonest conduct concerning its agents, suppliers, customers, or other business partners (or trading counterparts), and shall avoid transactions with any parties involved in dishonest conduct.
3. All contracts executed between the Company and its agents, suppliers, customers, or other business partners shall include clauses stipulating adherence to the ethical management policy. Furthermore, these contracts shall contain a provision allowing the Company to terminate or rescind the contract immediately should the counterparty be found to have engaged in dishonest conduct.

Article X. Prohibition of Bribery and Acceptance of Bribes

The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall, in the performance of their duties, neither directly nor indirectly offer, promise, request, or accept any improper benefits in any form from customers, agents, contractors, suppliers, public officials, or other stakeholders.

Article XI. Prohibition of Unlawful Political Donations

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall ensure that any direct or indirect donations made to political parties or organizations or individuals participating in political activities comply with the Political Donations Act and the Company's internal relevant operational procedures. Such donations shall not be made for the purpose of securing commercial benefits or transactional advantages.

Article XII. Prohibition of Inappropriate Charitable Donations or Sponsorships

The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall ensure that charitable donations or sponsorships comply with relevant laws and internal operational procedures, and shall not be utilized as a covert form of bribery.

Article XIII. Prohibition of Unreasonable Gifts, Hospitality, or Other Improper Benefits

The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall neither directly nor indirectly offer or accept any unreasonable gifts, hospitality, or other improper benefits for the purpose of establishing a business relationship or influencing commercial transactions.

Article XIV. Prohibition of Intellectual Property Infringement

The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall comply with relevant intellectual property laws and regulations, internal operational procedures, and contractual provisions. They shall not use, disclose, dispose of, destroy, or otherwise infringe upon intellectual property rights (IPR) without the consent of the IPR holder.

Article XV. Prohibition of Unfair Competition

The Company shall conduct its business activities in accordance with relevant competition laws and regulations. The Company shall not fix prices, manipulate bidding, restrict production and quotas, or share or divide markets by allocating customers, suppliers, operating regions, or types of business.

Article XVI. Prevention of Product or Service Harm to Stakeholders

1. The Company and its Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall, during the research and development, procurement, manufacturing, provision, or sale of products and services, comply with relevant laws, regulations, and international guidelines. They shall ensure the transparency and safety of product and service information, establish and publicly disclose a policy for protecting the rights and interests of consumers or other stakeholders, and implement this policy in their operating activities to prevent products or services from

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

directly or indirectly harming the rights, health, and safety of consumers or other stakeholders.

2. If there is sufficient evidence to suggest that the Company's products or services may jeopardize the safety and health of consumers or other stakeholders, the Company shall, in principle, immediately recall the batch of products or cease the provision of the services.

Article XVII. Organization and Responsibilities

1. The Company's Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall exercise the Duty of Due Care of a Prudent Manager, oversee the Company's prevention of dishonest conduct, and periodically review the effectiveness of implementation and continuously improve, thereby ensuring the realization of the ethical management policy.
2. To enhance the management of ethical business operations, the Company shall establish a dedicated unit subordinate to the Board of Directors, allocating sufficient resources and competent personnel. This unit shall be responsible for formulating and supervising the implementation of the ethical management policy and Prevention Programs. Its main responsibilities shall include the following matters, to be reported to the Board of Directors regularly (at least annually):
 - (1) Assisting in integrating ethical and moral values into the Company's business strategy, and developing relevant anti-corruption measures to ensure ethical management in line with legal and regulatory systems.
 - (2) Periodically analyzing and assessing the risk of dishonest conduct within the scope of operations, and based thereon, formulating Prevention Programs, and establishing related standard operating procedures (SOPs) and conduct guidelines within each program.
 - (3) Planning the internal organization, structure, and duties, and implementing a system of mutual supervision and checks and balances for business activities within the scope of operations that carry a higher risk of dishonest conduct.
 - (4) Promoting and coordinating integrity policy awareness and training.
 - (5) Planning the whistleblowing system (or reporting mechanism) to ensure its effectiveness.
 - (6) Assisting the Board of Directors and the management level in verifying and evaluating the effective operation of the preventive measures established for ethical management implementation, and periodically assessing the compliance status of relevant business processes, thereby

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

producing reports.

Article XVIII. Compliance in Business Execution

The Company's Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall, in the performance of their duties, comply with all legal requirements and the Prevention Programs.

Article XIX. Conflict of Interest

1. The Company shall establish a conflict of interest prevention policy to identify, monitor, and manage the risk of dishonest conduct potentially arising from conflicts of interest. The Company shall also provide appropriate channels for Directors, Managerial Officers, and other stakeholders attending or present at Board meetings to proactively disclose any potential conflicts of interest with the Company.
2. Should an agenda item presented to the Board of Directors involve the personal interests of a Director, Managerial Officer, or other stakeholder attending or present at the Board meeting, or the interests of the legal entity they represent, the individual shall explain the material content of the interest at that Board meeting. If there is a concern that the interest may impair the interests of the Company, the individual shall not participate in the discussion or voting, shall withdraw from the meeting during discussion and voting, and shall not exercise the voting rights on behalf of other Directors. Directors shall also exercise self-discipline and shall not inappropriately support one another.
3. The Company's Directors, Managerial Officers, Employees, Appointees, and Substantive Controllers shall not utilize their positions or influence within the Company to obtain improper benefits for themselves, their spouses, parents, children, or any other person.

Article XX. Accounting and Internal Control

1. The Company shall establish an effective accounting system and internal control system for business activities with a higher risk of dishonest conduct. The Company shall not maintain undocumented ledgers or retain secret accounts, and shall review these systems periodically to ensure their design and execution remain continuously effective.
2. The Company's internal audit unit shall formulate relevant audit plans based on the assessment results of the dishonest conduct risks. The plan shall

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

include the audit subjects, scope, items, and frequency, and shall be used to verify adherence to the Prevention Programs. The Company may appoint a Certified Public Accountant (CPA) to perform the audit, and, if necessary, may engage professional experts for assistance.

3. The results of the audit mentioned in the preceding paragraph shall be reported to the Senior Management and the dedicated ethical management unit, and an Audit Report shall be prepared and submitted to the Board of Directors.

Article XXI. Operational Procedures and Conduct Guidelines

In accordance with Article 6, the Company shall establish Operational Procedures and Conduct Guidelines that specifically regulate the matters requiring attention when Directors, Managerial Officers, Employees, and Substantive Controllers perform their duties. The content shall, at a minimum, cover the following:

- (1) Criteria for determining the offering or acceptance of improper benefits.
- (2) Procedures for handling lawful political donations.
- (3) Procedures and monetary standards for providing appropriate charitable donations or sponsorships.
- (4) Regulations for avoiding conflicts of interest related to duties, and the procedures for their declaration and handling.
- (5) Confidentiality regulations for confidential and commercially sensitive information obtained in the course of business.
- (6) Regulations and procedures for dealing with suppliers, customers, and business partners involved in dishonest conduct.
- (7) Procedures for handling the discovery of violations of the Corporate Ethical Management Principles.
- (8) Disciplinary measures to be taken against violators.

Article XXII. Education, Training, and Assessment

- i. The Company's Chairman, General Manager, or Senior Management shall regularly communicate the importance of integrity to Directors, Employees, and Appointees.
- ii. The Company shall periodically organize training and awareness programs for Directors, Managerial Officers, Employees, Appointees, and

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

Substantive Controllers, and invite business counterparts who engage in commercial activities with the Company to participate. This is to ensure they fully understand the Company's resolve for ethical management, its policies, Prevention Programs, and the consequences of dishonest conduct.

iii. The Company shall integrate the ethical management policy with employee performance assessment and human resource policies, establishing a clear and effective reward and disciplinary system.

Article XXIII. Whistleblowing System

The Company shall establish and strictly implement a specific whistleblowing system (or reporting mechanism). The content shall, at a minimum, cover the following:

- (1) Establishing and publicizing an internal independent mailbox or hotline, or engaging an external independent institution to provide a reporting mailbox or hotline, for use by both internal and external personnel.
- (2) Assigning dedicated personnel or a unit to receive reports. If the reported matter involves a Director or Senior Management, it shall be escalated to the Independent Directors. The system shall also stipulate categories of reported matters and their corresponding standard operating procedures for investigation.
- (3) Stipulating the subsequent actions to be taken after the investigation of a report is completed, based on the severity of the circumstances. Where necessary, reports shall be made to the competent authorities or submitted to the judicial authorities for prosecution.
- (4) Documentation and preservation of records regarding the acceptance, investigation process, investigation results, and related files of whistleblowing cases.
- (5) Confidentiality of the identity of the whistleblower and the content of the report, and allowing anonymous reporting.
- (6) Measures to protect whistleblowers from improper retaliation or adverse treatment due to the reporting incident.
- (7) Whistleblower incentive measures.

If the dedicated personnel or unit receiving reports discovers a material violation or a potential for material harm to the Company through investigation, a report shall be immediately prepared and the Independent

A Plus Biotechnology Co., Ltd.

Ethical Corporate Management Best Practice Principles

Directors shall be notified in writing.

Article XXIV. Disciplinary and Appeals System

The Company shall clearly stipulate and publish a disciplinary and appeals system for violations of the ethical management provisions, and shall promptly disclose information regarding the violator's job title, name, date of violation, content of violation, and handling status on the Company's internal website.

Article XXV. Information Disclosure

The Company shall establish quantitative data for promoting ethical management and continuously analyze and evaluate the effectiveness of the ethical policy implementation. The Company shall disclose its adopted measures for ethical management, the fulfillment status, the aforementioned quantitative data, and the implementation effectiveness on the Company's website, in the Annual Report, and in the Prospectus. The full content of the Ethical Management Principles shall also be disclosed on the Market Observation Post System (MOPS).

Article XXVI. Review and Amendment of Ethical Management Policy and Measures

The Company shall continuously monitor the development of ethical management regulations domestically and internationally, and encourage Directors, Managerial Officers, and Employees to submit suggestions. Based on these, the Company shall review and improve its established ethical management policy and implemented measures to enhance the overall effectiveness of ethical management.

Article XXVII. Enforcement

1. These Principles shall be implemented upon resolution by the Board of Directors and subsequent reporting to the Shareholders' Meeting. The same procedures shall apply to any amendments.
2. When the Company submits these Ethical Management Principles to the Board of Directors for discussion pursuant to the preceding paragraph, the opinions of all Independent Directors shall be fully considered, and any dissenting or qualified opinions shall be recorded in the Board meeting minutes. If an Independent Director is unable to personally attend the Board meeting to express a dissenting or qualified opinion, they shall issue a written opinion in advance, except in cases of justifiable reason, and it shall be recorded in the Board meeting minutes.
3. These Principles were established on April 10, 2023 (R.O.C. Year 112)